Clinical Evaluation of Niacin in Hemodialysis Patients with Hyperphosphatemia as Adjuvant to Calcium Carbonate
Background: The complications of End Stage Renal Disease ESRD attributed to high morbidity and mortality such as hyperphosphatemia and vascular disease. Vascular smooth muscle cells (VSMCs) are sensitive to elevation in serum phosphate levels and have the ability to modify their functions in respons...
Saved in:
Main Authors: | Rana Bahaa Mohammed (Author), Mohammed Mahmood Mohammed (Author), Sfaa Jameel Naeemah (Author) |
---|---|
Format: | Book |
Published: |
College of Pharmacy / Mustansiriyah University,
2020-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The efficacy and safety of niacin on hyperphosphatemia in ESRD patients undergoing hemodialysis: randomized controlled trial
by: Hanan Mahmoud Ahmed, et al.
Published: (2022) -
Niacin as a drug repositioning candidate for hyperphosphatemia management in dialysis patients
by: Shin S, et al.
Published: (2014) -
Elemental calcium intake associated with calcium acetate/calcium carbonate in the treatment of hyperphosphatemia
by: Rosamund J Wilson, et al.
Published: (2017) -
Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis
by: Vincenzo Savica, et al.
Published: (2008) -
Effect of niacin on phosphorus, calcium, parathormone and vitamin D levels in hemodialysis patients; a double-blinded randomized clinical trial
by: Ali Mohamadi Najafabadi, et al.
Published: (2023)